Figure 3From: Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literatureTreatment schedule. Sequential treatment with low-dose cytarabine (LDAC) 20 mg s.c. BID was conducted for 10 consecutive days followed by sorafenib 400 mg p.o. BID days 11–28.Back to article page